Search
for
Sort by
Research 451–480 of 683
- Teledermatology in the COVID-19 pandemic: A systematic review
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- Scalp Pruritus: Review of the Pathogenesis, Diagnosis, and Management
- Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
- Madarosis: A marker of many Maladies
- Natural Sources of Therapeutic Agents Used in Skin Conditions
- Two Mechanisms Regulate Keratin K15 Expression In Keratinocytes: Role of PKC/AP-1 and FOXM1 Mediated Signalling
- Experimental evaluation of ebastine, a second-generation anti-histamine, as a supportive medication for alopecia areata
- Erosive pustular dermatosis (chronic atrophic dermatosis of the scalp and extremities)
- Chronic graft versus host disease and skin
- The Role of Sex and Gender in Dermatology - From Pathogenesis to Clinical Implications
- Cepharanthine Suppresses Herpes Simplex Virus Type 1 Replication Through the Downregulation of the PI3K/Akt and p38 MAPK Signaling Pathways
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- Efficacy of Platelet-Rich Plasma Therapy in Oral Lichen Planus: A Systematic Review
- Cutaneous manifestations of COVID-19: a systematic review and analysis of individual patient-level data
- Poster Presentations
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management
- Nonhuman primate dermatology: a literature review
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Utilities of Botulinum Toxins in Dermatology and Cosmetology
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans
- Dermatotoxicology of microneedles (MNs) in man
- Skin manifestations associated with COVID-19
- Public interest in dermatologic symptoms, conditions, treatments, and procedures during the COVID‐19 pandemic: Insights from Google Trends
- Mucocutaneous manifestations in children with human immunodeficiency virus infection
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study